IL6 and serum lipopolysaccharide activity: The therapeutic potential of the mutant peptides in the clinical treatment of LPS-induced sepsis was reflected their ability to bind LPS directly and inhibit LPS-induced TNF-α and IL-6 release both in vitro and in vivo, promoting the survival rate of mice with endotoxemia.